Synaptogenix Inc (SNPX)

[XenaLives]

OK - that article was very helpful. It explains why the trials take so long, because they are looking for patients with a specific genetic trait.

Based on a number of BRNI pre-clinical and autopsy-validated human studies that have implicated PKC deficits as a cause of Alzheimer's disease, patient IV-18 was treated with the potent PKC epsilon activator, Bryostatin. This drug was administered by intravenous infusion once a week for the first three weeks of each month. Within two weeks of the initiation of treatment, patient IV-18 showed clinical improvements that included word vocalization, directed attentional focus, restoration of swallowing, increased responses to verbal commands, and some improvement of range of limb motion. These improvements persisted for approximately eight weeks, despite an episode of severe pneumonia that required intubation and hospitalization for four weeks.

BRNI was contacted by a West Virginian whose family suffered from high incidence of early onset dementia. Dementia in one family member, identified in study as IV-18, began at the age of 27 and included an inability to speak or swallow as well as immobilizing spasticity, although the patient retained some awareness and attentiveness. On behalf of the family member, BRNI sought and gained allowance from the Food and Drug Administration to proceed with compassionate treatment of patient IV-18 with Bryostatin, a drug that BRNI has been researching for over a decade, for treatment of cognitive disorders. The National Cancer Institute provided Bryostatin for this patient’s treatment.

Investigators at Marshall University’s School of Medicine working in close collaboration with BRNI constructed the pedigree of the West Virginia family in which members from five generations exhibited very early onset Alzheimer's dementia. By performing genomic analysis on blood samples from two of the West Virginia family members and comparing it with blood analysis from two family members in Michigan, the Marshall University Genomics Core researchers determined that this family has a unique expression of a very rare variant in the PSEN1 gene. This study provides the first description of the clinical presentation of patients with the variant earlier reported in French family (ALZ047).

http://www.j-alz.com/content/severe-alzheimers-patient-responds-bryostatin-treatment